Overcoming MET-mediated resistance in oncogene-driven NSCLC

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Targeted therapies are crucial for non-small cell lung cancer (NSCLC) treatment.
• Resistance to tyrosine kinase inhibitors (TKIs) is a significant clinical challenge in NSCLC.
• MET amplification/overexpression is an emerging mechanism of TKI resistance.

Purpose of the Study:

• To evaluate the efficacy of combining targeted therapies with MET or SHP2 inhibitors.
• To overcome MET-mediated resistance in diverse non-small cell lung cancer (NSCLC) subtypes.
• To assess the prevalence of MET amplification and overexpression in TKI-resistant NSCLC.

Main Methods:

• Prevalence study of MET amplification and overexpression in NSCLC patient samples post-TKI relapse.
• Confirmation of MET-mediated drug resistance in various mutant NSCLC cell lines (EGFR, KRAS, HER2, NTRK1).
• In vitro and in vivo assays to test combination therapies (targeted therapy + MET/SHP2 inhibitors).

Main Results:

• MET-mediated resistance was detected in 37.5% of tissue biopsies versus 7.4% of liquid biopsies.
• MET overexpression confirmed as a resistance driver in EGFR-, KRAS-, HER2-, and NTRK1-mutant NSCLC cell lines.
• Combination therapy with MET or SHP2 inhibitors successfully overcame MET-mediated resistance.

Conclusions:

• MET overexpression is a critical resistance mechanism in NSCLC treated with targeted therapies.
• Tissue biopsies are more effective than liquid biopsies for detecting MET overexpression.
• Combination strategies involving MET or SHP2 inhibitors hold promise for overcoming resistance and improving patient outcomes in NSCLC.